General Clinical Research Center

全科临床研究中心

• 批准号: 7229536
• 负责人: ERIK L HEWLETT
• 金额: $ 460.5万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-05-01 至 2011-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7229536
• 关键词: General; Clinical; Research; Center

EXCEED THE SPACE PROVIDED. Clinical investigation at the UVA GCRC is in its 31st year, and we request support for years 33-37. Our GCRC has longstanding strengths in neuroendocrinology, allergy, reproductive medicine, immunotherapy of cancer, and diabetes. These persist. In the past 2 years we have attracted a new cadre of GCRC investigators from Cardiology, vascular biology, and from the Center for Alternative Medicine program in the School of Nursing. With the recent recruitment of new research intensive leadership in our divisions of Cardiovascular Medicine, Hematology and Oncology, and our Department of Psychiatry and Behavioral Medicine, we anticipate continued growth and vitality of our research programs. In the past 2 years, we have also had major upgrades in our core assay program thereby facilitating sample throughput to >100,000/yr while freeing personnel time to implement additional analytical services. We have initiated a new GCRC imaging laboratory to allow studies of endothelial dysfunction in setting of diabetes, insulin resistance, and PCOS and microvascular perfusion in multiple organs including heart, muscle and kidney. The UVA GCRC has enjoyed an excellent record of productivity (>170 publications over the past 4 yrs). Its exercise, informatics and biomathematics cores have been national leaders in their innovative support for clinicalinvestigations. The GCRC enjoys a stable core of NIH-funded established investigators and is developing through our educational and mentoring programs another generation of skilled clinical investigators. We are particularly proud of our CAP and K award winners. During the last 3 years, we have seen (as has been a national trend) a growth in outpatient studies while inpatient studies, particularly those that have involved 24 hr blood sampling, have decreased. We have pro- actively begun working with the UVA Health System to plan a redesigned GCRC with expanded space and greater accessibility for outpatients that would accommodate current and projected usage.

超越空间 假如。 UVA GCRC 的临床研究已进入第 31 年，我们请求 33-37 年的支持。我们的 GCRC在神经内分泌学、过敏学、生殖医学、免疫治疗等方面具有长期优势 癌症和糖尿病。这些持续存在。在过去的两年里，我们吸引了 GCRC 的新骨干人员 来自心脏病学、血管生物学和替代医学项目中心的研究人员 护理学院。最近，我们的部门招募了新的研究密集型领导层 心血管医学、血液学和肿瘤学以及我们的精神病学和行为学系 医学方面，我们预计我们的研究项目将持续增长并充满活力。在过去的2年里，我们 我们的核心检测程序也进行了重大升级，从而提高了样品通量 >100,000/年，同时释放人员时间来实施额外的分析服务。我们发起了一个新的 GCRC 成像实验室可用于研究糖尿病、胰岛素抵抗、 多囊卵巢综合症和包括心脏、肌肉和肾脏在内的多个器官的微血管灌注。 UVA GCRC 拥有出色的生产力记录（过去 4 年发表了超过 170 篇出版物）。它是 运动、信息学和生物数学核心在创新支持方面一直处于国家领先地位 临床研究。 GCRC 拥有由 NIH 资助的稳定的研究人员核心，并且 通过我们的教育和指导计划培养新一代熟练的临床人员 调查人员。我们为 CAP 和 K 奖获得者感到特别自豪。 在过去 3 年中，我们看到（这已成为全国趋势）门诊研究的增长，同时 住院患者的研究，特别是那些涉及 24 小时血液采样的研究，已经减少。我们有亲 积极开始与 UVA 卫生系统合作，规划重新设计的 GCRC，扩大空间和 为门诊病人提供更大的便利性，以适应当前和预计的使用情况。